Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
The Human Polyomavirus, JCV, Uses Serotonin Receptors to Infect Cells
Gwendolyn F. Elphick,1William Querbes,1,2Joslynn A. Jordan,1,2Gretchen V. Gee,1,3Sylvia Eash,1,2Kate Manley,1,3Aisling Dugan,1,2Megan Stanifer,1,3Anushree Bhatnagar,4Wesley K. Kroeze,4Bryan L. Roth,4Walter J. Atwood1,2,3*
The human polyomavirus, JCV, causes the fatal demyelinatingdisease progressive multifocal leukoencephalopathy in immunocompromisedpatients. We found that the serotonergic receptor 5HT2AR couldact as the cellular receptor for JCV on human glial cells. The5HT2A receptor antagonists inhibited JCV infection, and monoclonalantibodies directed at 5HT2A receptors blocked infection ofglial cells by JCV, but not by SV40. Transfection of 5HT2A receptornegativeHeLa cells with a 5HT2A receptor rescued virus infection, andthis infection was blocked by antibody to the 5HT2A receptor.A tagged 5HT2A receptor colocalized with labeled JCV in an endosomalcompartment following internalization. Serotonin receptor antagonistsmay thus be useful in the treatment of progressive multifocalleukoencephalopathy.
1 Department of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912, USA. 2 Graduate Program in Pathobiology, Brown University, Providence, RI 02912, USA. 3 Graduate Program in Molecular Biology, Cellular Biology, and Biochemistry, Brown University, Providence, RI 02912, USA. 4 Department of Biochemistry, Case Western Reserve University Medical School, Cleveland, Ohio 44106, USA.
* To whom correspondence should be addressed. E-mail: Walter_Atwood{at}Brown.edu
The editors suggest the following Related Resources on Science sites:
In Science Magazine
LETTERS
Sandro Santagata, Hannah C. Kinney;, and Walter J. Atwood (15 July 2005) Science309 (5733), 381b.
[DOI: 10.1126/science.309.5733.381b] |Full Text »|PDF »
Evidence for Distinct Antagonist-Revealed Functional States of 5-Hydroxytryptamine2A Receptor Homodimers.
J. Brea, M. Castro, J. Giraldo, J. F. Lopez-Gimenez, J. F. Padin, F. Quintian, M. I. Cadavid, M. T. Vilaro, G. Mengod, K. A. Berg, et al. (2009)
Mol. Pharmacol.
75, 1380-1391
|Abstract »|Full Text »|PDF »
Identification and Characterization of Mefloquine Efficacy against JC Virus In Vitro.
M. Brickelmaier, A. Lugovskoy, R. Kartikeyan, M. M. Reviriego-Mendoza, N. Allaire, K. Simon, R. J. Frisque, and L. Gorelik (2009)
Antimicrob. Agents Chemother.
53, 1840-1849
|Abstract »|Full Text »|PDF »
Mirtazapine Use in Human Immunodeficiency Virus-Infected Patients With Progressive Multifocal Leukoencephalopathy.
Progressive multifocal leucoencephalopathy associated with lupus and methotrexate overdose.
D Shprecher, T Frech, S Chin, R Eskandari, and J Steffens (2008)
Lupus
17, 1029-1032
|Abstract »|PDF »
Progressive multifocal leukoencephalopathy - the importance of early diagnosis illustrated in four cases.
O Nived, A. Bengtsson, A Jonsen, and G Sturfelt (2008)
Lupus
17, 1036-1041
|Abstract »|PDF »
Progressive Multifocal Leukoencephalopathy in a Patient With Relapsed Acute Myelogenous Leukemia.
S. Kesari, S. Akar, A. Saad, J. Drappatz, I. J. Koralnik, and D. J. DeAngelo (2008)
J. Clin. Oncol.
26, 3804-3807
|Full Text »|PDF »
Schizophrenia Susceptibility Genes Directly Implicated in the Life Cycles of Pathogens: Cytomegalovirus, Influenza, Herpes simplex, Rubella, and Toxoplasma gondii.
Progressive multifocal leucoencephalopathy in a patient with sarcoidosis--successful treatment with cidofovir and mirtazapine.
K. Owczarczyk, R. Hilker, A. Brunn, M. Hallek, and A. Rubbert (2007)
Rheumatology
46, 888-890
|Full Text »|PDF »
Frequency and Phenotype of JC Virus-Specific CD8+ T Lymphocytes in the Peripheral Blood of Patients with Progressive Multifocal Leukoencephalopathy.
M. A. Lima, A. Marzocchetti, P. Autissier, T. Tompkins, Y. Chen, J. Gordon, D. B. Clifford, R. T. Gandhi, N. Venna, J. R. Berger, et al. (2007)
J. Virol.
81, 3361-3368
|Abstract »|Full Text »|PDF »
Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab Therapy: Possible Interventions.
O. Stuve, C. M. Marra, P. D. Cravens, M. P. Singh, W. Hu, A. Lovett-Racke, N. L. Monson, J. T. Phillips, J. W. C. Tervaert, R. A. Nash, et al. (2007)
Arch Neurol
64, 169-176
|Abstract »|Full Text »|PDF »
Functional Selectivity and Classical Concepts of Quantitative Pharmacology.
J. D. Urban, W. P. Clarke, M. von Zastrow, D. E. Nichols, B. Kobilka, H. Weinstein, J. A. Javitch, B. L. Roth, A. Christopoulos, P. M. Sexton, et al. (2007)
J. Pharmacol. Exp. Ther.
320, 1-13
|Abstract »|Full Text »|PDF »
Natalizumab and progressive multifocal leucoencephalopathy.
Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis..
S Vulliemoz, F Lurati-Ruiz, F-X Borruat, J Delavelle, I J Koralnik, T Kuntzer, J Bogousslavsky, F Picard, T Landis, and R A Du Pasquier (2006)
J. Neurol. Neurosurg. Psychiatry
77, 1079-1082
|Abstract »|Full Text »|PDF »
Human demyelinating disease and the polyomavirus JCV.
K Khalili and M K White (2006)
Multiple Sclerosis
12, 133-142
|Abstract »|PDF »
p90 ribosomal S6 kinase 2 exerts a tonic brake on G protein-coupled receptor signaling.
D. J. Sheffler, W. K. Kroeze, B. G. Garcia, A. Y. Deutch, S. J. Hufeisen, P. Leahy, J. C. Bruning, and B. L. Roth (2006)
PNAS
103, 4717-4722
|Abstract »|Full Text »|PDF »
Large-scale expression study of human mesial temporal lobe epilepsy: evidence for dysregulation of the neurotransmission and complement systems in the entorhinal cortex.
S. Jamali, F. Bartolomei, A. Robaglia-Schlupp, A. Massacrier, J.-C. Peragut, J. Regis, H. Dufour, R. Ravid, P. Roll, S. Pereira, et al. (2006)
Brain
129, 625-641
|Abstract »|Full Text »|PDF »
Involvement of Cytoskeletal Components in BK Virus Infectious Entry.